706 related articles for article (PubMed ID: 25517451)
21. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.
Karlan BY; Hawkins R; Hoh C; Lee M; Tse N; Cane P; Glaspy J
Gynecol Oncol; 1993 Nov; 51(2):175-81. PubMed ID: 8276290
[TBL] [Abstract][Full Text] [Related]
22. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
[TBL] [Abstract][Full Text] [Related]
23.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
24. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
25. [Detection of multi-focal breast carcinoma using 2[18F] fluoro-deoxy-D-glucose positron emission tomography (FDG-PET)].
Scharl A; Scheidhauer K; Pietrzyk U; Göhring UJ; Schomäcker K
Geburtshilfe Frauenheilkd; 1996 Aug; 56(8):434-7. PubMed ID: 8974899
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
[TBL] [Abstract][Full Text] [Related]
27. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
28. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?
Greven KM; Williams DW; Keyes JW; McGuirt WF; Watson NE; Case LD
Cancer J Sci Am; 1997; 3(6):353-7. PubMed ID: 9403048
[TBL] [Abstract][Full Text] [Related]
29. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer.
Izuishi K; Yamamoto Y; Sano T; Takebayashi R; Masaki T; Suzuki Y
J Gastrointest Surg; 2010 Jul; 14(7):1151-8. PubMed ID: 20443074
[TBL] [Abstract][Full Text] [Related]
30. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose.
Kole AC; Nieweg OE; van Ginkel RJ; Pruim J; Hoekstra HJ; Paans AM; Vaalburg W; Koops HS
Ann Surg Oncol; 1997 Jan; 4(1):57-63. PubMed ID: 8985518
[TBL] [Abstract][Full Text] [Related]
31. Overview of the current status of PET in breast cancer imaging.
Wahl RL
Q J Nucl Med; 1998 Mar; 42(1):1-7. PubMed ID: 9646639
[TBL] [Abstract][Full Text] [Related]
32. The role of PET/CT for evaluating breast cancer.
Yang SK; Cho N; Moon WK
Korean J Radiol; 2007; 8(5):429-37. PubMed ID: 17923786
[TBL] [Abstract][Full Text] [Related]
33. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging.
Lowe VJ; Kim H; Boyd JH; Eisenbeis JF; Dunphy FR; Fletcher JW
Radiology; 1999 Sep; 212(3):799-802. PubMed ID: 10478249
[TBL] [Abstract][Full Text] [Related]
34. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
35. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
Flanagan FL; Dehdashti F; Ogunbiyi OA; Kodner IJ; Siegel BA
Ann Surg; 1998 Mar; 227(3):319-23. PubMed ID: 9527052
[TBL] [Abstract][Full Text] [Related]
36. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
37. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
[TBL] [Abstract][Full Text] [Related]
38. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography.
Conti PS; Durski JM; Bacqai F; Grafton ST; Singer PA
Thyroid; 1999 Aug; 9(8):797-804. PubMed ID: 10482373
[TBL] [Abstract][Full Text] [Related]
39. Predicting location of recurrence using FDG, FLT, and Cu-ATSM PET in canine sinonasal tumors treated with radiotherapy.
Bradshaw T; Fu R; Bowen S; Zhu J; Forrest L; Jeraj R
Phys Med Biol; 2015 Jul; 60(13):5211-24. PubMed ID: 26083082
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of [
Zheng J; Yang Y; Ke H; Qian R; Liu Z; Miao W
Eur J Radiol; 2023 Dec; 169():111170. PubMed ID: 37925813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
